Q-omics provides the consensus-scored GSG1 profile across patient tissues and cancer cell-line models. GSG1 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, GSG1 is differentially expressed in 10, with the highest sampling consensus in KICH. Additionally, GSG1 RNA expression shows 12,401 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight MESO, KICH, and LSCC as cancer lineages where GSG1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for GSG1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes GSG1 survival associations across molecular data types. GSG1 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible GSG1 RNA expression–survival associations across cancer types. High GSG1 expression shows unfavorable associations in MESO, KIRC, LIHC, COAD and SCLC, but favorable associations in LAML. The MESO Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify MESO as the clearest survival context for GSG1 RNA expression.
This table summarizes GSG1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10. The strongest signals are observed in KICH for RNA.
This table ranks reproducible tumor–normal expression differences for GSG1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. GSG1 shows lower tumor expression in KICH, THCA, COAD and READ and higher tumor expression in KIRP and BRCA. The KICH box plot shows higher GSG1 RNA expression in normal versus tumor tissue (log2 FC = −0.928, t-test p < 0.001).
This table shows molecular features associated with GSG1 in patient tissues and cancer cell lines. In patient samples, GSG1 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, GSG1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUAD, while CRISPR and shRNA rows add functional-dependency signals in UPPER_AERODIGESTIVE_TRACT and BLOOD_Leukemia.
